Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 20.
doi: 10.1038/s41589-025-01929-w. Online ahead of print.

Accurate de novo design of high-affinity protein-binding macrocycles using deep learning

Affiliations

Accurate de novo design of high-affinity protein-binding macrocycles using deep learning

Stephen A Rettie et al. Nat Chem Biol. .

Abstract

Developing macrocyclic binders to therapeutic proteins typically relies on large-scale screening methods that are resource intensive and provide little control over binding mode. Despite progress in protein design, there are currently no robust approaches for de novo design of protein-binding macrocycles. Here we introduce RFpeptides, a denoising diffusion-based pipeline for designing macrocyclic binders against protein targets of interest. We tested 20 or fewer designed macrocycles against each of four diverse proteins and obtained binders with medium to high affinity against all targets. For one of the targets, Rhombotarget A (RbtA), we designed a high-affinity binder (Kd < 10 nM) despite starting from the predicted target structure. X-ray structures for macrocycle-bound myeloid cell leukemia 1, γ-aminobutyric acid type A receptor-associated protein and RbtA complexes match closely with the computational models, with a Cα root-mean-square deviation < 1.5 Å to the design models. RFpeptides provides a framework for rapid and custom design of macrocyclic peptides for diagnostic and therapeutic applications.

PubMed Disclaimer

Conflict of interest statement

Competing interests: D.W. is a cofounder of Priavoid and Attyloid. D.B. and G.B. are cofounders, advisors and shareholders of Vilya. The other authors declare no competing interests.

Update of

Similar articles

Cited by

References

    1. Vinogradov, A. A., Yin, Y. & Suga, H. Macrocyclic peptides as drug candidates: recent progress and remaining challenges. J. Am. Chem. Soc. 141, 4167–4181 (2019). - PubMed - DOI
    1. Muttenthaler, M., King, G. F., Adams, D. J. & Alewood, P. F. Trends in peptide drug discovery. Nat. Rev. Drug Discov. 20, 309–325 (2021). - PubMed - DOI
    1. Tsomaia, N. Peptide therapeutics: targeting the undruggable space. Eur. J. Med. Chem. 94, 459–470 (2015). - PubMed - DOI
    1. Atanasov, A. G., Zotchev, S. B. & Dirsch, V. M. International Natural Product Sciences Taskforce & Supuran, C. T. Natural products in drug discovery: advances and opportunities. Nat. Rev. Drug Discov. 20, 200–216 (2021). - PubMed - PMC - DOI
    1. Bhardwaj, G. et al. Accurate de novo design of membrane-traversing macrocycles. Cell 185, 3520–3532 (2022). - PubMed - PMC - DOI

LinkOut - more resources